ESOC 2022 Abstract Book

Citations of this article
Mendeley users who have this article in their library.

This article is free to access.


Background and aims: The aim of our study was to investigate the effect of cilostazol in combination with acetylsalicylic acid (ASA) in acute lacunar stroke (LS) resulting from cerebral small vessel disease (CSVD) on the levels of circulating endothelial microparticles (EMP). Methods: Comparative analysis of the levels of circulating EMP with phenotype CD309+, CD146+, CD144+, CD62E+ in the blood of 30 patients aged 56.3±8.2 years in the first 48 hours of LS resulting from CSVD and after 10 days of Cilostazol 100 mg 2 times a day in combination with ASA 75 mg 1 time a day. The comparison group consisted of 30 patients with LS taking ASA 300 mg per day, the control group - 15 healthy donors. Results: A significant increase in the levels of EMPs with the phenotype CD309+ (p=0.014), CD31+ (p=0.007), CD144+(p=0.05), CD146+ (p=0.046), CD62E+ (p=0.05) was found. After 10 days of dual antiplatelet therapy with cilostazol and ASA, normalization of EMP levels with the phenotype CD309+, CD144+, CD146+ and CD62E+ was established. After 10 days of ASA antiplatelet monotherapy, increased levels of EMP with phenotype CD309+ (p = 0.001), CD144+ (p = 0.001), CD146+ (p = 0.001) and CD62E+ (p = 0.001) persist relative to the data in the control group. Conclusions: The use of dual antiplatelet therapy cilostazol with ASA in acute LS resulting from CSVD led to normalization of EMP levels with the phenotype CD309+, CD144+, CD146+and CD62E+, reflecting a restoration of vascular endothelial cell permeability and blood-brain barrier integrity.




ESOC 2022 Abstract Book. (2022). European Stroke Journal, 7(1_suppl), 3–545.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free